Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Cancer Res. 2018 May 7;78(13):3522–3531. doi: 10.1158/0008-5472.CAN-17-4049

Figure 1. miR-339-5p expression levels are elevated in cells expressing chimeric FGFR1 kinases.

Figure 1

Analysis of miR-339-5p expression levels in SCLL cell lines, relative to their normal cell counterparts, shows highly significant upregulation (A). When the same four cell lines were treated with the BGJ398 FGFR1 inhibitor (B) there were significant reductions in miR-339-5p levels compared with DMSO-treated cells. Analysis of miR-339-5p expression levels in primary lymphomas from the BCR-FGFR1 (C, left) and ZMYM2-FGFR1 (C, right) mouse models compared with normal splenic cells, shows significant upregulation. * p = <0.05, ** p = <0.01, *** p = <0.001, **** p = <0.0001.